Thursday, December 31, 2015

IL-2 instructs allergen-specific tissue resident memory TH2 cell development

IL-2 is one of the first cytokines [interleukins] discovered and we still have no clear idea of the extent of its involvement and role within immune system. One reason has to do with the fact that IL-2 "in vitro" and IL-2 "in vivo" behave if completely 2 different cytokines.

So, if I see new paper that could tell us more about IL-2, I can't resist reading it. This week journal Immunity has published one such article. There, the authors showed that IL-2 signaling via its high-affinity receptor IL-2α (also known as CD25) directed development of allergen-specific tissue resident memory TH2 cells. I will discuss only those data that are relevant and unequivocal for the story.

For this study, the authors used class II tetramers and i.v. labeling techniques to identify and track house dust mite (HDM) allergen-specific tissue resident T cells. They showed that primary allergen exposure generates lung tissue resident HDM-specific tetramer-positive CD4 T cells.


These lung tissue resident tetramer-positive CD4 T cells expressed IL-13 upon HDM re-challenge (that identified them as TH2 cells).


Next, using parabiont mouse model the authors showed that tetramer-positive CD4 T cells found in allergen challenged lung tissue were bona fide non-circulatory resident-memory TH2 cells.


Finally, using WT:CD25KO mixed bone marrow chimera mice the authors showed that development of lung tissue resident memory TH2 cells required IL-2 signaling via its high-affinity receptor IL-2α.

In summary, this study suggests that IL-2 signaling via its high-affinity receptor IL-2α is mandatory for resident-memory TH2 cell development. This is addition to already known IL-2 roles in Foxp3+ Treg and memory CD8 T cell development. From therapeutic point of view, this is one big mess.

David Usharauli


1 comment:

  1. I am a complete responder to HD IL2, following a Stage IV kidney cancer diagnosis with 100s of mets in my lungs at time of diagnosis. That was in March of 2004. I had always been quite healthy, rarely had even a cold, only occasional allergies to pollen, etc. At the time of my diagnosis, there was only HD IL2 approved by the FDA for metastatic kidney cancer, so the decision to enter the treatment was easy. Or just go home and die...

    Why did I respond when so many others did not? Why do some have lasting stable disease, and those with partial responses stop responding? My own mets took over five months to completely disappear, an indication of my ongoing immune response. Patients are generally scanned within 3-4 weeks post an initial treatment, and without visible response, are denied the second half of the treatment. To stop the treatment based on the lack of an early and immediate response may prevent many such patients from getting an adequate reinforcement to their immune system.

    It is apparent that the stats which led to its FDA approval in 1992 reveal a limited understanding of the disease at the time, and the metrics now used to assess treatments. For example, a partial response required a 50% reduction in the metastases, whereas current measures would use a 30% shrinkage as a partial response. And there was no assessment of Stable Disease.


    I would love to discuss this idea with anyone who has an interest in high dose interleukin. As an 'exceptional responder', I feel a debt of gratitude to researchers and obligation to other patients. www.peggyRCC.com for my blog.
    Peggy Zuckerman

    ReplyDelete